RSNA 2022 CT Preview

CT tracks patient response to CAR T-cell therapy

By Kate Madden Yee, staff writer

Sunday, November 27 | 10:30 a.m.-11:30 a.m. | S2-SSNMMI01-3 | Room E352
In this session, German researchers will discuss how CT can help clinicians track patient response to chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma.

A team led by presenter Dr. Wolfgang Kunz of Ludwig-Maximilians-University of Munich in Germany conducted a study that included 26 patients who underwent a baseline CT exam before CAR T-cell therapy, then another CT scan at 30 days after treatment, and finally a PET/CT exam at three months. The investigators calculated the sum of target lesion volume to assess treatment efficacy.

CT showed effective response to CAR T-cell treatment between the 30 days and three months post-treatment time frames (p < 0.05), which led the investigators to conclude that, since CAR T-cell therapy has "emerged as a new effective antigen-driven cell-based immunotherapy to treat patients with diffuse large B-cell lymphoma," tracking treatment response with CT can help better guide patient care.

Want to learn more? Stop by this Sunday morning talk to get all of the details.

Copyright © 2022

Last Updated mf 11/22/2022 2:51:32 PM